--- title: "【True Insight Hong Kong Stock Market】United Laboratories International Holdings Limited (03933.HK) net profit continued to grow by 16.1% to RMB 1.49 billion, dividend increased by 33.3% year-on-year." type: "Topics" locale: "zh-CN" url: "https://longbridge.com/zh-CN/topics/23562040.md" description: "$UNITED LAB(03933.HK) announced its interim results for the six months ended June 30, 2024. During the period, the group recorded revenue of RMB 7.18 billion, up 3.9% year-on-year. Gross profit increased by 4.1% to RMB 3.344 billion. EBITDA was RMB 2.23 billion, up 14.2% year-on-year. Profit attributable to owners of the company was RMB 1.49 billion, up 16.1% year-on-year..." datetime: "2024-08-30T01:25:28.000Z" locales: - [en](https://longbridge.com/en/topics/23562040.md) - [zh-CN](https://longbridge.com/zh-CN/topics/23562040.md) - [zh-HK](https://longbridge.com/zh-HK/topics/23562040.md) author: "[真灼财经](https://longbridge.com/zh-CN/profiles/1067948.md)" --- > 支持的语言: [English](https://longbridge.com/en/topics/23562040.md) | [繁體中文](https://longbridge.com/zh-HK/topics/23562040.md) # 【True Insight Hong Kong Stock Market】United Laboratories International Holdings Limited (03933.HK) net profit continued to grow by 16.1% to RMB 1.49 billion, dividend increased by 33.3% year-on-year. $UNITED LAB(03933.HK) announced its interim results for the six months ended June 30, 2024. During the period, the Group recorded revenue of RMB 7.18 billion, up 3.9% year-on-year. Gross profit increased by 4.1% to RMB 3.344 billion. EBITDA was RMB 2.23 billion, up 14.2% year-on-year. Profit attributable to owners of the Company was RMB 1.49 billion, up 16.1% year-on-year. The increase in net profit was mainly driven by higher revenue from intermediate products and continued reduction in production costs, which boosted gross profit, as well as lower sales and distribution expenses, which offset the increase in R&D costs. Earnings per share were RMB 82.08 cents. The Board proposed an interim dividend of RMB 16.0 cents per share for the six months ended June 30, 2024, with an interim payout ratio of 19.5%, up 2.5 percentage points year-on-year. During the period, the Group's intermediate and API segments recorded external sales revenue of RMB 1.314 billion and RMB 3.464 billion, up 25.4% and 1.2% year-on-year, respectively. Overseas export sales recorded revenue of RMB 1.427 billion, up 4.8% year-on-year, accounting for 19.9% of the Group's total revenue. Production costs in the upstream segment continued to improve, and the advantages of the industrial chain became more evident. The Group maintained its leading position in the domestic and export markets for intermediates and APIs. The Group continued to optimize its industrial structure and practice transformation and upgrading in the upstream segment. In April 2024, the Group's wholly-owned subsidiary, Inner Mongolia Guangda Lianfeng Biotechnology Co., Ltd., commenced construction of a long-chain dicarboxylic acid bio-based new materials project, which will accelerate diversified technological innovation and industrial upgrading. In addition, the Zhuhai United Laboratories Gaolan Port API project, which started construction in November 2023, is progressing smoothly, with multiple workshops having completed roof sealing. The project is expected to be completed and put into operation in 2025. During the period, sales revenue from finished dosage forms was RMB 2.398 billion, down slightly by 1.6% year-on-year. Diabetes drugs recorded total sales revenue of approximately RMB 546 million, up 9.5% year-on-year. Among them, human insulin recorded sales revenue of RMB 219 million, while insulin analogs collectively recorded sales revenue of RMB 327 million, with sales volume maintaining rapid growth. During the period, the Group's full range of insulin products was selected as Category A in the National Drug Centralized Procurement (Insulin Special Continuation), with the procurement base volume increasing significantly by 52.5%. All Category A selected products will also receive allocations of remaining volumes. During the period, the Group established a health products division, which has now laid out four product lines: general dietary supplements, cross-border nutritional supplements, health foods, and medical devices. Existing products cover categories such as joint nutrition, intestinal regulation, cardiovascular health, vision protection, and immunity enhancement. In addition to offline channels, the Group is rapidly expanding online channels such as e-commerce platforms, live streaming platforms, and new retail platforms to build a benchmark brand in the health consumption sector. The Group continued to accelerate the development of its animal health business, with animal health products recording sales revenue of RMB 671 million, up 25.7% year-on-year. During the period, the Group signed a cooperation agreement with New Zealand pet food factory New Zealand Riverland Foods Ltd, entering the high-end pet food market through this collaboration and introducing high-quality prescription wet food from New Zealand to China. This cooperation also marks the Group's animal health business beginning to expand into international markets. In addition, the construction of new animal health bases is progressing smoothly, with workshops in the new Inner Mongolia animal health plant entering trial operation stages; multiple workshops at Zhuhai United Animal Health have completed roof sealing; and the main civil construction of the Henan Lianmu Veterinary Drug Base has been completed, with supporting and other facilities under construction. The Group has established a comprehensive R&D system, including platforms for biological R&D, chemical drug R&D, innovative drug R&D, animal health R&D, clinical research, and external cooperation. Currently, there are 44 human drug products under development, including 19 Class 1 new drugs, focusing on endocrinology, metabolism, autoimmunity, ophthalmology, and anti-infection. There are 60 new animal health products under development, covering pets, livestock, poultry, and aquaculture. In addition, generic drug quality and efficacy consistency evaluations, medical aesthetics, and pharmaceutical excipients projects are also progressing steadily. During the period, the Group invested a total of RMB 479 million in drug R&D, with R&D expenses up 36.9% year-on-year. Among Class 1 new drug projects, TUL01101 tablets and TUL01101 ointment completed the first patient enrollment for Phase II clinical trials, and TUL12101 eye drops completed Phase I clinical trials. In addition, the diabetes indication for semaglutide injection completed Phase III clinical trials, and the first patient enrollment for degludec insulin liraglutide injection was completed for Phase III clinical trials. In terms of generic drug quality and efficacy consistency evaluations, during the period, the Group's imipenem cilastatin sodium for injection (specifications: 0.5g, 1.0g) and amoxicillin clavulanate potassium tablets (specification: 0.375g) successively passed consistency evaluations. The Group will continue to advance new drug R&D and consistency evaluation work to provide patients with more safe and high-quality medication options. Looking ahead, Mr. Cai Haishan, Chairman of United Laboratories, concluded: "Against the backdrop of deepening healthcare system reforms, the Group will consolidate its core industrial advantages, further strengthen its vertically integrated industrial layout, and continuously enhance scientific research and innovation capabilities, while optimizing diversified business layouts and resource allocation to achieve long-term sustainable development. Looking forward, the Group is confident in consolidating and enhancing its industry position and influence amid the waves of change in China's pharmaceutical industry, and is committed to creating more value for shareholders and society." ### 相关股票 - [UNITED LAB (03933.HK)](https://longbridge.com/zh-CN/quote/03933.HK.md) - [Hang Seng Index (00HSI.HK)](https://longbridge.com/zh-CN/quote/00HSI.HK.md)